Biomarkers in lung cancer screening: the importance of study design

David R. Baldwin (Lead / Corresponding author), Matthew E. Callister, Philip A. Crosbie, Emma L. O'Dowd, Robert C. Rintoul, Hilary A. Robbins, Robert J. C. Steele

Research output: Contribution to journalEditorialpeer-review

Abstract

In most randomised controlled trials of low radiation dose computed tomography (LDCT) screening for lung cancer, eligibility has been determined by age and tobacco smoking criteria [1, 2]. A number of multivariable risk prediction models have been developed that are more sensitive and specific, but are still heavily dependent on smoking and age [3]. Some have been used successfully in trials and pilot programmes and have yielded higher detection rates, although they may also select people with more comorbidities [4-6]. Using biomarkers to select people for lung cancer screening is an important area for research because it offers the possibility to identify those at high risk who are not eligible for screening by conventional criteria, while avoiding further investigation in those who do not have malignant disease. This means that the impact of the intervention as a whole could be greater (more lives saved) and harms, due to the screening of low-risk people or those without cancer, could be avoided. Two biomarkers intended for use in lung screening are presented in this issue of the European Respiratory Journal.

Original languageEnglish
Article number2004367
JournalEuropean Respiratory Journal
Volume57
Issue number1
Early online date14 Jan 2021
DOIs
Publication statusPublished - Jan 2021

Keywords

  • lung cancer screening
  • biomarkers
  • methodology of clinical trials

Fingerprint

Dive into the research topics of 'Biomarkers in lung cancer screening: the importance of study design'. Together they form a unique fingerprint.

Cite this